CD24 genetic variants contribute to overall survival in patients with gastric cancer

Table 4 Distributions of genotypes according to clinical parameters in gastric cancer cases

	P-534			P value	P170			P value	P1527		P value
	C/C	C/A	A/A		C/C	C/T	T/T		TG/TG	TG/del
n	181	358	140		295	308	76		559	120
Age	60 (53-70)	61 (54-71)	61 (55-70)	0.715	61 (53-71)	61 (54-70)	63 (56-70)	0.658	61 (54-70)	60 (51-71)	0.307
Sex
Male	27.3	50.3	22.4	0.092	43.9	44.2	11.9	0.485	83.6	16.4	0.172
Female	25.0	58.9	16.1		42.2	48.4	9.4		79.2	20.8
H. pylori
Positive	26.3	53.4	20.3	0.905	42.6	46.1	11.3	0.769	82.3	17.7	0.996
Negative	27.0	51.6	21.4		45.6	43.7	10.7		82.3	17.7
Differentiation
Poor	24.7	55.8	19.5	0.070	43.5	47.4	9.2	0.055	81.5	18.5	0.500
Moderate to well	30.2	46.0	23.8		45.0	40.1	14.8		83.7	16.3
TNM stage
I-II	26.2	52.8	21.0	0.999	45.1	44.7	10.2	0.695	82.4	17.6	0.986
III-IV	26.3	52.6	21.1		42.7	45.2	12.1		82.4	17.6
Pathologic type
Tubular adenocarcinoma	26.4	52.3	21.3	0.754	45.0	43.9	11.2	0.173	82.8	17.2	0.751
Signet ring cell	26.0	60.0	14.0		34.0	60.0	6.0		80.0	20.0
Other	27.9	50.0	22.1		38.2	47.1	14.7		85.3	14.7
Distant metastasis
Positive	32.3	48.5	19.2	0.323	40.4	44.4	15.1	0.374	79.8	20.2	0.454
Negative	25.1	53.9	20.9		44.3	45.2	10.5		82.9	17.1
CD24 staining	60 (0-120)	60 (0-120)	100 (20-140)	0.215	60 (0-120)	60 (20-120)	40 (0-100)	0.482	60 (0-120)	60 (40-100)	0.922

Data are presented as percentage of total or median (25^th to 75^th percentiles).